Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
Patmore LA, van Eekhout KMA, Buti M, Koc ÖM, Agarwal K, de Knegt RJ, Janssen HLA, van der Valk M, Lieveld FI, Hansen BE, Kramer M, de Bruijne J, Claassen MAA, Smit C, de Man RA, Takkenberg B, Carey I, Sonneveld MJ; HARP study group and HepNed. Patmore LA, et al. Among authors: agarwal k. J Hepatol. 2024 Feb;80(2):243-250. doi: 10.1016/j.jhep.2023.10.019. Epub 2023 Oct 26. J Hepatol. 2024. PMID: 37898348 Free article.
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS Jr, Hézode C, Rizzetto M, Paraná R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J. Buti M, et al. Among authors: agarwal k. Gastroenterology. 2014 Mar;146(3):744-753.e3. doi: 10.1053/j.gastro.2013.11.047. Epub 2013 Dec 4. Gastroenterology. 2014. PMID: 24316262 Free article. Clinical Trial.
Reply.
Carey I, Cloherty G, Dusheiko G, Agarwal K. Carey I, et al. Among authors: agarwal k. Hepatology. 2021 Feb;73(2):870-871. doi: 10.1002/hep.31468. Hepatology. 2021. PMID: 33118625 No abstract available.
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE).
Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE Study Group. Sonneveld MJ, et al. Among authors: agarwal k. Clin Gastroenterol Hepatol. 2022 Apr;20(4):e784-e793. doi: 10.1016/j.cgh.2020.12.005. Epub 2020 Dec 10. Clin Gastroenterol Hepatol. 2022. PMID: 33309804 Free article.
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis.
Brunetto MR, Carey I, Maasoumy B, Marcos-Fosch C, Boonstra A, Caviglia GP, Loglio A, Cavallone D, Scholtes C, Ricco G, Smedile A, Riveiro-Barciela M, van Bömmel F, van der Eijk A, Zoulim F, Berg T, Cornberg M, Lampertico P, Agarwal K, Buti M. Brunetto MR, et al. Among authors: agarwal k. Aliment Pharmacol Ther. 2021 Mar;53(6):733-744. doi: 10.1111/apt.16258. Epub 2021 Jan 19. Aliment Pharmacol Ther. 2021. PMID: 33465257 Free article.
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B; CREATE study group. Sonneveld MJ, et al. Among authors: agarwal k. J Hepatol. 2022 May;76(5):1042-1050. doi: 10.1016/j.jhep.2022.01.007. Epub 2022 Jan 29. J Hepatol. 2022. PMID: 35092743 Free article.
1,390 results